Karachi: BF Biosciences Limited has introduced Continuous Glucose Monitoring (CGM) devices in Pakistan through a collaboration with SIBIONICS, a China-based medical technology company. The launch, under the brand name Sibionics CGM, marks a significant step in diabetes management in the region.
The announcement, dated August 20, 2026, was made in compliance with Sections 96 and 131 of the Securities Act, 2015, and Clause 5.6.1(a) of the PSX Rule Book, providing transparency and alignment with shareholder inquiries and digital media coverage.
SIBIONICS, established in 2015, has garnered a substantial global presence in CGM technology. According to information published by SIBIONICS, its products and services are accessible in over 100 countries, reaching more than 4 million users worldwide. CGM technology offers continuous monitoring of glucose levels, providing valuable insights into glucose patterns influenced by diet, physical activity, and other lifestyle factors. This technology aids patients and healthcare professionals in making informed decisions for diabetes and lifestyle management.
BF Biosciences’ launch of Sibionics CGM aligns with their strategy to develop an integrated approach to metabolic care. The technology is designed to complement the Company’s existing metabolic portfolio, which includes Ferulin (Insulin), Sematide® (Semaglutide), and Zeptide (Tirzepatide), under the guidance of healthcare professionals.
The Company emphasizes the integration of medicines, devices, and disease awareness initiatives such as SlimPossible, aiming for a comprehensive approach to managing diabetes, obesity, and related metabolic conditions. This aligns with BF Biosciences’ commitment to Putting Patients First.
According to information available from the Pakistan Stock Exchange (PSX), BF Biosciences is dedicated to keeping its shareholders and the stock exchange informed of any material developments per applicable laws and regulations.